ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market

ITM’s long-term partner RadioMedix is producing and distributing GeGant® for the U.S. market

GARCHING, Germany & MUNICH & HOUSTON--(BUSINESS WIRE)--ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechnology company, announced today that ITM has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for ITM’s next generation Germanium-68/Gallium-68 (68Ge/68Ga) Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant®.

 

 

RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators
in U.S. and Canada

Houston, TX, USA and Garching, Germany. RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.   The OncoBeta® Tungsten (Wolfram)-188/Rhenium-188

 

RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)

Houston, Jan. 02, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National Institute of Health (NIH) SBIR/STTR

 

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

Houston and St Louis, Jan. 07, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that the New Drug Application for copper Cu 64 dotatate injection was filed with the U.S.

 

 

 

 

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

LAUSANNE, Switzerland--(BUSINESS WIRE)--Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision

 

RadioMedix and Vect-Horus Announce Signing of a Letter of Intent to Co-Develop a Radio-Theranostic Agent for Glioblastoma

MARSEILLE, France & HOUSTON--(BUSINESS WIRE)--Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of

 

RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.

Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical, 64Cu-Dotatate, was granted Fast Track designation by the U.S. Food

 

 

 

 

RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers

Houston, TX (January 21th, 2019) – RadioMedix Inc. is pleased to announce that the company has been awarded a two-year, $2.0 M Phase II SBIR contract award by the NIH NCI (HHSN261201800048C; UPIID:75N91018C00048) for the

 

RadioMedix presented at the 2018 BIO Investor Forum in San Francisco

(Houston, December 14, 2018). RadioMedix Inc has been selected by the National Cancer Institute (NCI) Small Business Innovation Research Development Center (SBIR) to participate in 2018 BIO Investor Forum. The company received federal funds from

 

RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix(TM) for the treatment of neuroendocrine tumors

Houston (TX U.S.), Courbevoie (France), November 13th, 2018. RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company) announced today that the United States Food & Drug Administration (FDA) has granted

 

 

 

 

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Houston, TX (January 21th, 2019) – RadioMedix Inc. is pleased to announce that the company has been awarded a two-year, $2.0 M Phase II SBIR contract award by the NIH NCI (HHSN261201800048C; UPIID:75N91018C00048) for the